Page 171 - Read Online

Yang et al. Hepatoma Res 2023;9:48 https://dx.doi.org/10.20517/2394-5079.2023.68 Page 21 of 21

and clinical research. Ann Oncol 2019;30:1417-27. DOI
90. Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Hum Pathol 2014;45:1630-8. DOI
91. Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and
future perspectives. World J Gastrointest Oncol 2021;13:332-50. DOI PubMed PMC
92. Berchuck JE, Facchinetti F, DiToro DF, et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced
biliary tract cancer. Ann Oncol 2022;33:1269-83. DOI
93. Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-
positive intrahepatic cholangiocarcinoma. Cancer Discov 2019;9:1064-79. DOI
94. Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against
FGFR-deregulated tumors. Cancer Res 2020;80:4986-97. DOI
95. Calvert AE, Chalastanis A, Wu Y, et al. Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence
of mutation. Cell Rep 2017;19:1858-73. DOI PubMed PMC
96. Intlekofer AM, Shih AH, Wang B, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature
2018;559:125-9. DOI PubMed PMC
97. Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase
inhibition. Cancer Discov 2018;8:1540-7. DOI PubMed PMC
98. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013;19:1401-9. DOI PubMed
99. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-
positive intrahepatic cholangiocarcinoma. Br J Cancer 2019;120:165-71. DOI PubMed PMC
100. Bahleda R, Italiano A, Hierro C, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor
receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res 2019;25:4888-97. DOI PubMed
101. Kim SB, Meric-Bernstam F, Kalyan A, et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor
2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target Oncol 2019;14:591-601. DOI PubMed PMC
102. Ahn DH, Uson Junior PLS, Masci P, et al. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced
cholangiocarcinoma. Invest New Drugs 2022;40:134-41. DOI
103. Lee CK, Chon HJ, Cheon J, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and
cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol
2023;8:56-65. DOI